Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for KAI-7535 (GLP-1 Agonist) in Obesity. The expected timing is based on the latest available company guidance and may change.
05/26/26:- Global Ph2 began. Hengrui Ph3 obesity data expected later in 2026. Global Ph2 data 2027. 07/07/26:- Reported positive Ph3 topline in China. Global Ph2 trial data expected in 2027. 08/12/26:- Global Ph2 remains ongoing; data is expected in 2027. HARBOR-1 Ph3 obesity results were positive.
Verification
Confirm timing and program details against the company announcement or filing.